Reuters logo
BRIEF-Merck enters exclusive worldwide license agreement with Teijin Pharma
2017年5月25日 / 中午12点15分 / 6 个月前

BRIEF-Merck enters exclusive worldwide license agreement with Teijin Pharma

May 25 (Reuters) - Merck & Co Inc:

* Merck enters exclusive worldwide license agreement with Teijin Pharma for investigational antibody candidate targeting TAU

* Merck & Co Inc - under terms of agreement Merck will have exclusive world-wide rights to develop, manufacture and commercialize anti-TAU antibody.

* Says Teijin Pharma will receive royalties on product sales and retains an option to co-promote an approved product in Japan

* Merck & Co Inc - will make an upfront payment to Teijin Pharma who is also eligible to receive development, regulatory and sales milestone payments

* Merck & Co Inc - Merck will make an upfront payment to Teijin Pharma who is eligible to receive development, regulatory and sales milestone payments Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below